echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > JCSM: Iron carboxymaltose can effectively correct iron deficiency in patients with pulmonary hypertension

    JCSM: Iron carboxymaltose can effectively correct iron deficiency in patients with pulmonary hypertension

    • Last Update: 2021-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pulmonary arterial hypertension (PAH) is a progressive disease, and the survival time of patients is limited
    .


    Iron deficiency (ID) is related to disease severity and mortality


    Researchers retrospectively analyzed the effects of intravenous infusion of carboxymaltose iron (FCM) on the combined ID of stable targeted PAH therapy (ferritin <100 μg/L or ferritin 100-300 μg/L and transferrin saturation [ TSAT] <20%) the iron status of PAH patients and the influence of clinical measures were compared with those of PAH patients without ID
    .


    Patients with ID received a single dose of FCM (500-1000 mg) infusion


    The effect of FCM supplementation on serum iron and ferritin

    The effect of FCM supplementation on serum iron and ferritin

    A total of 117 PAH patients (average 60.
    9±16.
    1 years old, 64.
    1% women) who received stable targeted therapy for ≥3 months with a clearly diagnosed disease were included , of which 58 had ID and 59 had no ID
    .


    FCM iron supplementation in PAH patients with ID can improve the iron status immediately and last for up to 18 months (the p values ​​of serum iron, ferritin, and TSAT are all <0.


    diagnosis

    Changes in the six-minute walking distance of the two groups of patients

    Changes in the six-minute walking distance of the two groups of patients

    At the 6th and 18th months after FCM infusion, the six-minute walking distance of patients in the FCM group increased from 377.
    5±15.
    9 meters at baseline to 412.
    5±15.
    1 meters and 400.
    8±14.
    5 meters, respectively (p<0.
    05)
    .


    The WHO functional classification and ESC/ERS risk status of patients in the FCM group also improved (p=0.


    At the 6th and 18th months after FCM infusion, the six-minute walking distance of patients in the FCM group increased from 377.


    PAH-related hospitalization rates before and after intervention in the two groups

    PAH-related hospitalization rates before and after intervention in the two groups

    For patients with pulmonary hypertension with iron deficiency, in addition to the treatment of PAH, it seems feasible and safe to correct iron deficiency by supplementing iron outside the stomach and intestines through FCM.
    It has a sustained beneficial effect on iron status and may improve the patient’s condition.
    Clinical status, reduce hospitalization rate
    .


    A larger-scale controlled study is needed to verify the results of this study


    For patients with pulmonary hypertension with iron deficiency, in addition to the treatment of PAH, it seems feasible and safe to correct iron deficiency by supplementing iron outside the stomach and intestines through FCM.


    Original source:

    Kramer Tilmann,Wissmüller Max,Natsina Kristiana et al.


    Ferric carboxymaltose in patients with pulmonary arterial hypertension and iron deficiency: a long-term study in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.